Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy

• Published in: Circulation Journal 2024/01/25, Vol.88(2), pp.217-225
• Main Authors: Moriyama, Shohei, Hieda, Michinari, Kisanuki, Megumi, Kawano, Shotaro, Yokoyama, Taku, Fukata, Mitsuhiro, Kusaba, Hitoshi, Maruyama, Toru, Baba, Eishi, Akashi, Koichi, Fukuda, Haruhisa
• Format: Article
• Language: English
• Subjects: Adverse events; Cardio-oncology; Humans; Hypertension; Hypertension - drug therapy; Neoplasms - drug therapy; Signal Transduction; Vascular endothelial growth factor (VEGF); Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors - adverse effects; VEGF signaling pathway (VSP) inhibitors
• ISSN: 1346-9843; 1347-4820; 1347-4820
• DOI: 10.1253/circj.CJ-22-0628

Background: Hypertension is a frequent adverse event caused by vascular endothelial growth factor signaling pathway (VSP) inhibitors. However, the impact of hypertension on clinical outcomes during VSP inhibitor therapy remains controversial.Methods and Results: We reviewed 3,460 cancer patients treated with VSP inhibitors from the LIFE Study database, comprising Japanese claims data between 2016 and 2020. Patients were stratified into 3 groups based on the timing of hypertension onset: (1) new-onset hypertension (n=569; hypertension developing after VSP inhibitor administration); (2) pre-existing hypertension (n=1,790); and (3) no hypertension (n=1,101). Time to treatment failure (TTF) was used as the primary endpoint as a surrogate for clinical outcomes. The median (interquartile range) TTF in the new-onset and pre-existing hypertension groups was 301 (133–567) and 170 (72–358) days, respectively, compared with 146 (70–309) days in the non-hypertensive group (P